>PROKKA_00001 Clostridium P-47 protein
MQTTTLNWDTVYAVPINIVNEAIKLKHPTPENFELLNGKYGNCSGSFEDWQITNGGDGSN
IRLKIPIKNFKATIIGNRLNGKGGFAFANLEVQVKLKYLPHFPQSKNKDIELVDLKIRTQ
SDNPEDPAIIVISSYKNIQGFYFEDEYKLTEDDEFVVSYFYRLIKEWLEKNLHFFNYIFN
TVNLNLYISDKEKWEWTKPSYVDYAYSEIEGDLSKSALGVLCMTGGRTGSKNQQQKIDPY
AIPKKSQSGFLISEERLLRNILLPTIPKKFPKSKGDEFEVINESSQGGGYSYILKLKQGK
KIDLENIQAAGYTCTPYIQKMKIYLLGSYLKLETTTRVDLPLGVASICETTCEYKFKLAT
NNKGEQTIAYEQIGSPVNIQYSENTGNVGLNIVVSFLSITLSFALSFVSGFGTFLAVGLI
GGCLIGSVALIPTFIESYNSDTAPSIDLSLENSVSEITWNSSDVFNLDYVALAGPLQLGG
ILQVQNS*
>PROKKA_00002 Clostridium P-47 protein
MKKIYYKFHKGGILMTNLKSYIIYDWKETILKNSKDNYSINEIIPKTFSKKICGGRFLNS
TLSGNWKSWTLTDEAEGPHPILKCTIDNGYLEIYSNTSSEKHSLKDIEIKICMAIKPNSD
GTHSLCKNSFYIKSNSLKLSEDRLIVSHYLEKLILAWFKDNHKYIELFINRSRIQTRVEG
DLSLLGWDIESSVSYKTMNEFIKKDNLYEKKFHQYMEVRRNEYTIDGEFGPWQMTTGADG
QNIRFLCPIKSATYKINDDVYIAKPDNFIIIQVDLKYFDSKTTIIDPSGLNNGQQFNLKV
KTDSTDEINAVILVGSRITDVNEDLYPGDDVSLEIVFKTWFNANIQKFTQIFSYILLNET
SKIPEYQWLKPTQISYGSASVTMPDPSNPNKELSNLDASTFAAMAMVENHKNDRPNHAVD
NRFLELSKTPAAVAISMPEFLKHFLVNGLQAMQIDNLDAFEVSSENLMITNKKKINFGKI
QAQKRQVDTLIEPNNFKMAIQNNQVILEIVDATWQQVEGVTGHFGYRQAYNLILKNENNV
YKPVLEESGEVTLSYFVTEEAWKTRQDAIISATVSIIVGTIIGALSSIGSDKLYKFLKSK
YVVNKNKASMKLSGKDIKEISSMIDVPEAELLSIRRKNSKTSLDDISLMSSNGSTSPGDI
SIMQNKPRALGERLQIAGLKLLGGLITSFGYTIGFILPEVLKDVINANINNDFKVLPGIQ
EFSQQCIGPVQWPENGELKINFAKLQGVYLLGGNLVKTLKTN*
>PROKKA_00003 hypothetical protein
MELKQAFVFEFDENLSSSSGSIHLEKVKQNCSPNYDYFKITFIDGYLYIKNKSGVILDKY
DLNNVISLVALKKDYLSLSLSNNKQIKKFKNIKNKHLQNKFNLYVINEDIEKKITKNGIL
EEVILNKMLLSILLGNEENLLQIS*
>PROKKA_00004 Clostridium P-47 protein
MNTYGWDIVYGCSNRVVNKHLKNYIDENKIEFLYSDINKKQEIKMIFDNWEIINGGTSNF
LRIKIFIKEGYFKFRNTTVDLSGVIPILEIKLDFFNDASNPHIKELKFSFGNKTNDDIKV
IVSDLSGKLYEEDEFYFNKLLISAFINNEKQVSYIFASLNVTSNIVWMNPKQFKFVYYSP
TDNNDGYLCILSVVTNRDISKLSTNVDSSILSENSEVGLLISEKLFMENLLLPKLSSNMG
SNITSNNFNVINTSDTTGIIKNKNTLNWYGIKVAALYYYPEINDFSMELFEGNKLKTRLS
GIVKLTGYERIYSKLNMECITKFIYDNKNKKVSFEIYSTPIMECRPIFGLLDGIPAAVAK
SVGNWSLKSFRDSLAFELANNFTDIINDIVNWNNLKISEVTNIILNVGFCIQGNMN*
>PROKKA_00005 Tetanus toxin precursor
MKINGNLNIDSPVDNKNVAIVRSRKSDVFFKAFQVAPNIWIVPERYYGESLKINEDQKFD
GGIYDSNFLSTNNEKDDFLQATIKLLQRINNNVVGAKLLSLISTAIPFPYENNTEDYRQT
NYLSSKNNEHYYTANLVIFGPGSNIIKNNVIYYKKEYAESGMGTMLEIWFQPFLTHKYDE
FYVDPALELIKCLIKSLYYLYGIKPNDNLNIPYRLRNEFNSLEYSELDMIDFLISGGIDY
KLLNTNPYWFIDKYFIDTSKNFEKYKNDYEIKIKNNNYIANSIKLYLEQKFKINVKDIWE
LNLSYFSKEFQIMMPERYNNALNHYYRKEYYVIDYFKNYNINGFKNGQIKTKLPLSKYNK
EIINKPELIVNLINQNNTVLMKSNIYGDGLKGTVDNFYSNYIIPYNLNYEHSINYSYLDN
VNIEEIEKIPPINDEDIYPYRKNADTFIPVYNITKAKEINTTTPLPVNYLQAQMIDSNDI
NLSSDFLKVISSKGSLVYSFLNNTMDYLEFIKYDKPIDTDKKYYKWLKAIFRNYSLDITE
TQEISNQFGDTKIIPWIGRALNILNTNNSFVEEFKNLGPISLINKKENITIPKIKIDEIP
SSMLNFSFKDLSENLFNIYCKNNFYLKKIYYNFLDQWWTQYYSQYFDLICMASKSVLAQE
KLIKKLIQKQLRYLMENSNISSTNLILINLTTTNTLRDISNQSQIAINNIDKFFNNAAMC
VFENNIYPKFTSFMEQCIKNINKSTKEFILKCTNINETEKSHLIMQNSFSNLDFDFLDIQ
NMKNLFNSYTELLIKEQTSPYELSLYAFQEQDNNVIGDTSGKNTLVEYPKDIGLVYGINN
NAIHLTGANQNIKFTNDYFENGLTNNFSIYFWLRNLKQNTIKSKLIGSKEDNCGWEIYFE
NDGLVFNIIDSNGNEKNIYLSNISNNSWHYIVISINRLKDQLLIFIDNILVANEDIKEIL
NIYSSDIISLLSDNNNVYIEGLSVLNKTINSNEILTDYFSDLNNSYIRNFDEEILQYNRT
YELFNYVFPEIAINKIEQNNNIYLSINNENNLNFKPLKFKLLNTNPNKQYVQKWDEVIFS
VLDGTEKYLDISTTNNRIQLVDNKNNAQIFIINNDIFISNCLTLTYNNVNVYLSIKNQDY
NWVICDLNHDIPKKSYLWILKNI*
>PROKKA_00006 Botulinum neurotoxin type E precursor
MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGTTPQDFHPPTS
LKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTP
DNQFHIGDASAVEIKFSNGSQDILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHGFGS
IAIVTFSPEYSFRFNDNSMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPL
ITNIRGTNIEEFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK
DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLATKFQVKCRQTYIGQYKYFKL
SNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPITGRGLVKKIIRFCKNIVSVKG
IRKSICIEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILNFNSESA
PGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNLTSS
IDTALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIADIS
IVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSSDNK
NKVIKAINNALKERDEKWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKTIIE
SKYNSYTLEEKNELTNKYDIKQIENELNQKVSIAMNNIDRFLTESSISYLMKLINEVKIN
KLREYDENVKTYLLNYIIQHGSILGESQQELNSMVTDTLNNSIPFKLSSYTDDKILISYF
NKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYPTNKNQFGIYNDKLSEVNI
SQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGWKVSLNHNEII
WTLQDNAGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDQKSILNL
GNIHVSDNILFKIVNCSYTRYIGIRYFNIFDKELDETEIQTLYSNEPNTNILKDFWGNYL
LYDKEYYLLNVLKPNNFIDRRKDSTLSINNIRSTILLANRLYSGIKVKIQRVNNSSTNDN
LVRKNDQVYINFVASKTHLFPLYADTATTNKEKTIKISSSGNRFNQVVVMNSVGNNCTMN
FKNNNGNNIGLLGFKADTVVASTWYYTHMRDHTNSNGCFWNFISEEHGWQEK*
>PROKKA_00007 Helix-turn-helix domain protein
MNRNIIGKKVRIIRKLKNLTQEELIAIIQLKCLSIDRPMLSRIETDSREVYDFEVKAIAE
ALDISVDELFIQN*
>PROKKA_00008 Replication-associated recombination protein A
MTPLAERMRPTKLEDFVGQKQIIGEGKPLYNIIKSKNIVNCILYGPPGTGKTTLANIMAN
YVDRKFYKLNATTASVKDIQEIASSLDTLLGYNGVVVYIDELQHFSKKQQQSLLEFIEKG
QITLIASTTENPYFVLHKAILSRCNIFTFKPLTTDDIKFGVVKAIERAIENGMEIKYTDD
AISYIAEISQGDYRKAYNILELGIISSLKRTLEITAEYIEELEQSHIRFDASGDEFYNSL
SALQKSIRGSDVDAAIHYLARLIKSGNLTAIVRRLGVIVAEDIGLAHPNALTVVNSGLEL
VLKVGLPEAQLILSELVIYLATLPKSNSAYLAIKSAMQDLENKNVGDVPMHLKDAHYSGA
QKLGVGGYKYPHDYSNNYVKQQYMPQELRDTIYYIPQENKYEGSIKNYWKNIKE*
>PROKKA_00009 hypothetical protein
MGKAGRKENCNISDNDMLVALERYTREFPNEKINIKKLADFSGIERHYWYSRKGLREKIE
EINSISYEKYDIISDGDRKKIKFPNVDEVVDNNFRNKKRLKFILNSFFLTYQDFYESSCE
AYKLKKDINILKDKIIKYEDEIQKLKNERDKFRELSNYNENKYYEIAIRSRERNFRKENN
IKSNVIEINNKNIKAYSTDEDDLDSLLNRIDD*
>PROKKA_00010 hypothetical protein
MNNKQQYKLALRGGLLVNQIANNSDSLVIVTKELKIYKEEELDYYKEKFNYFKKKGRIVN
CVFNDLIWTLSETDEGGYKSNRNIKFSINFINKNNIIKAYLINLLINLININTIVERVRV
VSDIINISNFFDIDKFNEFEEYIESTFDNNKLNMKDYTMNFISFIRDNVDEEYCNYLVSL
PNEYFSKTREIPDYTSILKFDFLLDKYLKNSDEKEFFRYYPIVLWWKICSKIPLRPCEFM
ILKKDCVYEKNRKYYIRIRRCKPHGFVNKALNIRKEQSFRINKEIYDLVMKVVSHKSHDC
EFLLSKNLYNKYYTQYTYKEELVQGRVMRSYNLDKCLKDFYYYEINNKNIQTVISKKDVK
ESLSQQFYRDCMVSLQLGDARHLAIINLVLQGTNSYLIREMCGHRDINSHLHYIDHAKTY
ITSKVLVLTDIRKLEIKLANIYSNESFEYGNKRNNKVSNLLYNEYKKVGDIYCKRYVGRE
EMFPFLCLTDCDECNDKVETDFTGNNDEEIKINKMEIERQFQIIEKYLKDAQFNSIIDSK
NERVLFDSQKNIEESANKLNYLISKEAELEAKIFFGGIITKEE*
>PROKKA_00011 hypothetical protein
VIELEDAAKEINPKCYKYFMKKLKTLNNINIFDKNGKLFITKNDFEKLKRNKASKIPYHI
DIPNGYASRNEAVKKYNLNYNSLRHNEEKGIIKTAISGGIAFLEKESIEKHIEFLKYIEK
INNDDNWIKVSSLRGKPYYDRISYTVRRNDFKNDLIKIGIGRTAEFFITRKLYKEIINGK
HKIIVTSQHKKKILKDDIEGIITKLLIETGVNSIRQKAKMKQLIKVKEISELSGIDYEEI
IESRRYFNGEIVKEQNIEYMHRYDIENIMKNFGYYSIKKLSKICEISFSTLIRDFNIANF
LGIYINFKIDKDFFVDINGVEIILKEFSKNYIATLTLDEIYRERMKLFPDEFFKTYKLAD
EFIVKKKRNCYRPYGEDTTSYNRVINSIENLVNYLDKEIFEYSAEELLKLVSNTNIVKRG
YQAHVCQFINYVKRKMRNDCEYNKVFGLTLLTQYKIEKGENYLEKIYDKETWSKYYILLK
DIDKHIVNAIKDPRYAQSWLYCILNLSVTWRKKNIILSLPRIKLQEIGVYEFEWFSSKNV
FTYSMAELVLNQIKFSLDGVIAYKNRRHLHINIPMSLKIPTAIAFIICEIHCREKSKDNI
MYELAQSYIRKSDYKKLFEDDKLLNFENLKCTRSIISYGFSHAINTIGTVPAAYKIYSNR
RSHSDSEQKITNVTGDHYIALDGIENGAKEFMFHVVERGAFGFMYYKLFKCFFDKKDFEN
ISQEQLTDLTKYSDQILNPRTLENIADKFIENDRINKLSIFEILWYSSIIKNKGKRDLSS
KSNIFLAIMIDLYKKQSEDLLGKSDEFKTFVDEKYLQLDAEIEDILKNKISTSKIIDNIL
NGSNCCYSKDTNCIFDRIERKELCPYKYEDNGGKSCVGCKYNLLTVYALNEINEKMQTLL
DKIQKKSYFTKEEIQKIAIY*
>PROKKA_00012 hypothetical protein
VFIISNVIELRNTNSKYRFKVKVCKYKREGRCEDHLFQKAIIVLFDNITGKSRVHEFTEF
AIREFGKNRIKTQVDYLGKLVKFLNYVIKNKDKKNFKYLDFYDVEEFSQEIALDVQMNTF
NIYKMVLSRFYRYLAQKEWLINVSINDFIIKESEKNGGVMINYDIPICNIDIPDNIHRRN
THVMEYELQAMLLEVAIEEVNIIALAIFFQMFGGLRSGEIVNLTHSAVQCIGTYGRYGML
LDITDRNLRLDLKNNQAKGYSKKSRKQKVISPFNMLEKIYIQHMKKYKCVDDSGAIFVNK
DGMPMTIGSYNYYFDKLKKIFLKRLKESDNPTLKVQGDILCAAKWKTHIGRGIFSNNLGE
FMSASELKIARGDKYINSSDSYIEETKKIGKLYEENAEGAFQLLIKKINE*
>PROKKA_00013 Replication-associated recombination protein A
MSPLADLMRPSKIEDFVGQRHILGKNTPLYNLIKSKKICNCIFYGPPGTGKTTLANIMAK
YVDKKFYKLNATTASVKDIQNITSELDNLLNYAGVVLYIDELC*
>PROKKA_00014 molybdenum cofactor biosynthesis protein MoaC/MOSC-domain-containing protein
VQGFNLKALPIGSVLTCGNIILEITQIGKECHAHCEIYKKMGECIMPTNGVFAKVIEGGQ
MKIGDEIEIASGIEKMY*
